Consistently, we also identified MARCKS as a HER2 interactor in an additional HR-negative, HER2-positive tumor specimen (Case 3), supporting its potential relevance in more aggressive, hormone receptor-negative disease contexts. Here, ERBB2 is linked to neoplasm.